NCT03443895View on ClinicalTrials.gov

Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 8, 2018

Primary Completion Date

May 1, 2018

Study Completion Date

May 1, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

AEF0117 oral capsule

0.6, 2 and 6mg of AEF0117

DRUG

Placebo oral capsule

Matching placebo capsule

Trial Locations (1)

07103

Biotrial Inc, Newark

Sponsors

Lead Sponsor

Aelis Farma
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Aelis Farma

INDUSTRY

NCT03443895 - Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117 | Biotech Hunter | Biotech Hunter